Author(s) PANTHERx Rare
Fierce Biotech recently featured PANTHERx® Rare in the article, “De-Risking a Rare Disease Launch Starts with Precision,” exploring why the risks of rare disease commercialization continue well beyond FDA approval and how a purpose-built Rare Pharmacy model can help manufacturers reduce those risks. The article examines the challenges of patient access, fragmented care, and complex reimbursement, and explains how specialized expertise, coordinated support, and personalized patient engagement can improve outcomes while helping maximize a therapy’s long-term value.